Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Altimmune

Novavax

They're risky but could deliver huge returns in the new year.

3 Coronavirus Stocks Poised to Soar in 2021

Cardiff Oncology

These clinical-stage drug developers were unstoppable last year.

3 Healthcare Stocks That Turned $100,000 Into $1 Million in 2020

Co-Diagnostics

Not all of them were COVID-19 vaccine makers.

These Were the 3 Best Coronavirus Stocks of 2020

Genprex

Trillium Therapeutics

The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opportunity in the form of SARS-CoV-2, the virus that causes COVID-19.

5 Biotech Stocks That Generated 1,000%+ Returns In 2020

BioNTech SE

Inovio Pharmaceuticals

Moderna

Telesis Bio Inc

We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.

6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19

Celldex Therapeutics

Retractable Technologies

These stocks have made investors richer by posting explosive revenue growth or advancing significantly in high-impact programs.

These 5 Small-Cap Healthcare Stocks Gained the Most in 2020

A10 Networks

National Vision Hlds

FuelCell Energy

Smith & Wesson Brands

Unisys

VirnetX

XBiotech

These are the small cap stocks with the best value, fastest growth, and most momentum for January 2021.

Top Small Cap Stocks for January 2021

They are at a critical point. What happens next could push them higher, or result in a big loss.

Is There Still Room for Growth for These 2 Coronavirus Stocks?

Arcturus Therapeutics

CureVac B.V

Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.

4 Small COVID-19 Vaccine Makers to Look Out for in 2021

GoodRx Holdings

Teladoc

It's been a great ride for these three in 2020, but there are clouds on the horizon.

3 Healthcare Stocks to Sell Before 2021

They each have a key competitive edge that could set them apart.

3 COVID-19 Vaccine Stocks That Could Be the Biggest Winners in a Post-Pandemic World

Seres Therapeutics

Nestle SA

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

These Were the 10 Best Healthcare Stocks of 2020

Johnson & Johnson

Pfizer

Whether you're aggressive, risk-averse, or somewhere in between, here are some coronavirus vaccine stocks you might want to consider.

COVID Vaccine Stock Ideas for Different Investors

A COVID-19 vaccine in tablet form would be a game-changer in the fight against the pandemic.

Up Almost 2,000% in 2020, Is Vaxart Still a Buy?

BioDelivery Sciences

BioMarin Pharmaceutical

Catalyst Pharmaceuticals

Innoviva

Vertex Pharmaceuticals

Voyager Therapeutics

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Top Biotech Stocks for Q1 2021

If data from upcoming human trials for Vaxart's vaccine candidate are positive, you might have a second chance.

Did You Miss Out on a 2,000% Gain with Vaxart Stock?

Vaccine makers of all sizes and development stages face crucial news this month.

3 Top Coronavirus Stocks to Watch in December

Vir Biotechnology

They'll be later to market than rivals. But if their product candidates are stronger, investors may reap rewards.

2 Ultra-Risky Coronavirus Stocks That Could Make You Filthy Rich

Citi Trends

Louisiana-Pacific

Nautilus

Ultra Clean

These are the small cap stocks with the best value, fastest growth, and most momentum for December 2020.

Top Small Cap Stocks for December 2020

Here's what makes these coronavirus-focused biotechs stand out.

3 COVID Vaccine Stocks That Could Be Millionaire-Makers

In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to gain from their vaccine development efforts.

4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts

Aprea Therapeutics

Viking Therapeutics

Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.

3 Stocks with Jaw-Dropping Growth Potential

Title: An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus

Vaxart Hosting Key Opinion Leader Panel Call for Investors

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that management will be participating in two upcoming virtual investor conferences and invites investors to participate by webcast. Please see additional details below:

Vaxart Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference

Enrollment in Phase 1 for Oral COVID-19 Vaccine Trial Completed

Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update

News for Vaxart Stock (VXRT)